NK cell-mediated cytotoxicity modulation by A(2) adenosine receptor agonist in different mammalian species

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Adenosines accumulate extracellularly during metabolic stress (ischemia, inflammation, cell damage).
• Adenosine signaling primarily inhibits innate immunity, impacting infectious and neoplastic diseases.
• Tumor-derived adenosine impairs anti-tumor immune cells (e.g., lymphocytes) and promotes tumor growth via angiogenesis.

Purpose of the Study:

• To investigate the impact of A(2) adenosine receptor (A(2)AR) agonists on cytotoxic immune cell responses.
• To compare these effects across different mammalian species (humans, rodents, pigs, goats).
• To assess responses in both healthy and cancer conditions.

Main Methods:

• Administration of an A(2)AR agonist to immune effector cells.
• Evaluation of cytotoxic activity in human and other mammalian species.
• Comparison of responses in healthy versus cancer-associated immune cells.

Main Results:

• The A(2)AR agonist induced a dose-dependent inhibition of cytotoxic activity in all tested species.
• Variability in inhibitory effects was noted depending on the species and specific target cells.
• Adenosine receptor signaling significantly impacts immune cell function.

Conclusions:

• The A(2) adenosine receptor (A(2)AR) is central to adenosine-mediated immune suppression in tumors.
• Targeting A(2)AR may represent a strategy to overcome tumor-induced immune evasion.
• Species-specific differences in A(2)AR function warrant consideration in therapeutic development.